Single-Cell Dissection of BCAA Metabolism Unveils ACAT1-Dependent CS Acetylation as a Metabolic Checkpoint for Immunosuppression in Prostate Cancer

Why It Matters

Linking BCAA metabolism to immune evasion reveals a novel checkpoint that can be exploited to improve prostate‑cancer immunotherapy and metabolic‑targeted strategies.

Key Takeaways

• BCAA‑HIGH prostate tumors show reduced CD8⁺ T‑cell infiltration.
• ACAT1 drives citrate synthase acetylation, boosting citrate production.
• Elevated citrate creates an immunosuppressive tumor microenvironment.
• ACAT1 expression correlates with poor prognosis in TCGA prostate cohort.
• Targeting ACAT1 may combine metabolic inhibition with immunotherapy.

Pulse Analysis

Branched‑chain amino‑acid catabolism has long been recognized as a fuel for tumor proliferation, yet its impact on the immune landscape of prostate cancer remained murky. By leveraging single‑cell transcriptomics, researchers mapped BCAA metabolic activity across individual tumor cells and linked high BCAA flux to a marked decline in cytotoxic CD8⁺ T‑cell presence. This granular view clarifies how metabolic heterogeneity within a tumor can dictate immune cell recruitment, offering a more precise biomarker than bulk tissue analyses.

The mechanistic core of the discovery centers on ACAT1, an enzyme traditionally associated with cholesterol esterification. In the context of elevated BCAA, ACAT1 catalyzes the acetylation of citrate synthase, a key TCA‑cycle enzyme, thereby amplifying citrate synthesis. The surplus citrate not only fuels biosynthetic pathways but also acts as a signaling metabolite that dampens T‑cell activation and promotes regulatory immune subsets. This metabolic‑immune crosstalk establishes a checkpoint that enables prostate tumors to evade immune surveillance while simultaneously accelerating growth.

Therapeutically, the ACAT1‑CS acetylation axis opens a dual‑front avenue: inhibiting ACAT1 could blunt tumor metabolism and restore a more permissive immune microenvironment. Combining ACAT1 inhibitors with checkpoint blockade or adoptive T‑cell therapies may overcome the resistance observed in advanced castration‑resistant prostate cancer. Ongoing challenges include developing selective ACAT1 modulators and identifying patient subsets with BCAA‑HIGH signatures, but the study provides a compelling rationale for integrating metabolic reprogramming into next‑generation prostate‑cancer treatment regimens.